US FDA puts clinical hold on Neumora Therapeutics' brain disease study due to convulsions in rabbits.

Neumora Therapeutics' shares fell after the US FDA put a clinical hold on an early-stage study of its brain disease treatment following safety findings of convulsions in rabbits. The study involved about 30 patients who received doses of the drug NMRA-266, with no convulsions observed in any participant. The company is working with the FDA to resolve the clinical hold and will provide updates when available.

April 15, 2024
14 Articles

Further Reading